RxDoctor Payments Data

Monica Rodriguez, MD

Endocrinology, Diabetes & Metabolism · Phoenix, AZNPI 1568451839

Payments from drug & device makers

$1,315in general payments, 2019–2025

Across 27 payments — averaging $48.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$311
  • Corcept Therapeutics$272
  • UCB, Inc.$230
  • Ferring Pharmaceuticals Inc.$149
  • E.r. Squibb & Sons, L.L.C.$131
  • Medtronic$109
  • plus $114 from 3 others

What the payments were for

  • Food & beverage$1,30099%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,315 in reported general payments places this provider in the 35th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

See all endocrinology, diabetes & metabolism providers in Arizona

Medicare billing

Part B allowed, 2024
$168,644
Medicare patients
175
Services billed
12,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Somatuline DepotLanreotide Acetate11$173,403
Teriparatide38$94,878
GenotropinSomatropin31$78,960
ForteoTeriparatide17$66,399
MounjaroTirzepatide30$31,661
TymlosAbaloparatide12$30,377
XyostedTestosterone Enanthate27$20,603
OmnitropeSomatropin13$15,931
OzempicSemaglutide13$13,917
Hydrocortisone167$9,246
Cabergoline54$5,959
Testosterone32$4,477
Desmopressin Acetate36$3,411
SynthroidLevothyroxine Sodium21$2,106
Tirosint-SolLevothyroxine Sodium12$1,936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Radius Health, Inc.Tymlos$15$30,37712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

Other endocrinology, diabetes & metabolism in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →